IPG PHOTONICS CORP Q4 FY2024 earnings call

Mark Gitin noted Q4 revenue was at the high end of guidance, gross margin improved, and operating expenses were better than expected. The company underwent a strategy review to strengthen products, penetrate new markets, and introduce novel solutions. They introduced a new high-power fiber laser platform with next-gen pump diodes, acquired Clean Laser to accelerate laser-based cleaning systems. R&D focuses on urology, micromachining, and other key applications with TAM over $5B. The company is strengthening customer intimacy, optimizing go-to-market, and enhancing service strategy.

In the fourth quarter, revenue came in at the top of guidance at $234 million, up slightly sequentially. Gross margin was 38.6%, an increase of 40 basis points year-over-year. Revenue was down 22% year-over-year and 18% excluding divested operations. Foreign currency reduced revenue by ~1%. Revenue from materials processing applications decreased 24% YoY (welding, cutting, marking down; additive manufacturing and micromachining up). Revenue from other applications decreased 6% (medical down, advanced up). By region: North America up 6% QoQ, down 31% YoY; Europe up 5% QoQ, down 22% YoY; China down 10% QoQ, 22% YoY. Welding was 37% of 2024 total sales, cutting 21%, medical bounced back in Q4 but was down for the year.

For Q1 2025, revenue is expected to be $210 million to $240 million. Gross margin is between 36% and 39%. Operating expenses in Q1 are between $82 million and $84 million, expected to increase in Q2 and remain elevated. Adjusted EPS is in the range of $0.05 to $0.35. Adjusted EBITDA is between $19 million and $35 million. 2025 CapEx is between $105 million and $115 million, related to manufacturing capacity in Germany.

Macro conditions in industrial and automotive markets (EV) pose challenges. Increased competition in cutting is a risk. Geopolitical uncertainties, such as weak bookings in Korea, impact results. Tariff uncertainties affect manufacturing and supply chain dynamics.

Q: Ruben Roy asked about cutting, new products, and visibility.

A: Mark Gitin discussed new high-power lasers, differentiation in key growth areas, and visibility tied to industrial market recovery.

Q: Jim Ricchiuti inquired about OpEx, medical growth, and Japan.

A: Tim Mammen spoke about OpEx increases, Mark Gitin detailed medical product launch and new OEM in urology, and Tim provided insights on Japan's volatile revenue.

Q: Keith Housum asked about high-power laser cost-cutting, tariffs, and volume vs price.

A: Mark Gitin talked about new lasers rolling out, Tim discussed tariff flexibility, and Mark addressed cutting market recovery.

Q: Michael Feniger questioned auto/eMobility, tariffs, and adjusted EPS.

A: Tim provided auto/eMobility size details, Mark highlighted differentiation in EV, and Tim explained amortization add-back in adjusted EPS.

Q: Scott Graham asked about cutting market and adjusted EPS add-back.

A: Mark and Tim discussed defending cutting business and amortization add-back in adjusted EPS.

Q: Mark Miller inquired about margin improvement and non-laser sales.

A: Tim and Mark spoke about margin efforts and non-laser sales timing.